Continuous Renal Replacement Therapy Market Analysis

Continuous Renal Replacement Therapy Market Analysis

Continuous renal replacement therapy market size from the continuous venovenous hemodialysis (CVVHD) is expected to reach USD 1 billion by 2032. CVVH is an effective and adaptable therapy for critically ill AKI (acute kidney injury) patients as it offers continuous renal support, offering more progressive and continuous filtration of patients' blood flow. It is useful for a wide spectrum of AKI patients due to its capacity to adjust therapy to specific patient demands. Widespread acceptability and significant adoption across critical care settings will fuel the segment expansion.
 

The consumables segment held significant continuous renal replacement therapy market share in 2022 and is estimated to witness considerable growth to reach around USD 1.3 billion by 2032. Hemofilters and dialyzers are critical CRRT consumables that filter waste products, excessive fluids, and electrolytes from the patient's blood flow. The widespread adoption of high-performance filters has increased the efficacy of CRRT, resulting in improved patient outcomes. Furthermore, the higher availability of government schemes and reimbursement rules will accelerate the segment growth. For instance, in India, the Pradhan Mantri National Dialysis Program provided dialysis services to a total of 17.27 lakh beneficiaries as of December 31, 2022.
 

North America continuous renal replacement therapy market size exceeded USD 371 million in 2022 and will record substantial growth through 2032 owing to the increasing demand for CRRT among the expanding senior population prone to renal failures. According to NIDDK estimates, the incidence of CKD in those aged 65 and more in the U.S. is 14%, meaning that approximately 1 in every 7 adults aged 65 and more have CKD. Furthermore, the rising per capita incomes and healthcare spending will have beneficial impact on the regional market outlook.